As the AI race heats up, could it be a “watershed” moment for the software stocks? We debate and give you some names to buy. Plus, why the new administration could be bullish for small caps. And, Teva’s CEO discusses the company’s outlook, transition and the future of drug pricing negotiations.
As the AI race heats up, could it be a “watershed” moment for the software stocks? We debate and give you some names to buy. Plus, why the new administration could be bullish for small caps. And, Teva’s CEO discusses the company’s outlook, transition and the future of drug pricing negotiations.